VivoSeq
Other

Movement Disorder

16

Pipeline Programs↗

4

Active Trials↗

11

Companies Involved↗

Movement Disorder is an emerging landscape with 16 programs across 11 companies. The most active players are Merck & Co., Mylan Pharmaceuticals Inc, Biogen. 4 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

6/100

Mech. Concentration

13/100

Completion Rate

33/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 2Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc

1 program

Phase 2Biogen logo

Biogen

1 program

Phase 3Ultragenyx logo

Ultragenyx

1 program

Phase 3A

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

1 program

Phase 3UCB logo

UCB

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

12

clinical trials

Terminated4 · 33%
Recruiting4 · 33%
Unknown status2 · 17%
Completed2 · 17%

Clinical Trials

Trial Activity

12 trials

Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders.
Recruiting·PPirogov Russian National Research Medical University·Phase 1/2·NCT07363603·5 enrolled
Phenotype/Genotype Correlations in Movement Disorders
Recruiting·National Institute of Neurological Disorders and Stroke (NINDS)·N/A·NCT00018889·2,500 enrolled
A Rigid Body Database on Human Movement
Recruiting·National Institutes of Health Clinical Center (CC)·N/A·NCT00001252·7,500 enrolled
Natural History Protocol for Movement Disorders
Recruiting·National Institute of Neurological Disorders and Stroke (NINDS)·N/A·NCT05413291·4,000 enrolled
Movement Disorders Caused by Antipsychotic Drugs in Older Patients
Completed·UUniversity of California, San Diego·Phase 1·NCT00255879·250 enrolled
A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders
Completed·AAvid Radiopharmaceuticals·Phase 2/3·NCT01550484·170 enrolled
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
Terminated·Merck & Co. logoMerck & Co.·Phase 2·NCT00686699·11 enrolled
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
Terminated·Biogen logoBiogen·Phase 3·NCT05418673·7 enrolled
Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Terminated·Ultragenyx logoUltragenyx·Phase 3·NCT02960217·44 enrolled
Oral Iron Frequency for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder
Terminated·MMayo Clinic·Phase 4·NCT04610827·6 enrolled
Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders
Unknown status·—·N/A·NCT05486806·50 enrolled
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
Unknown status·NNucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara·Phase 2/3·NCT03790345·45 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)